Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

     
    Press Releases
      Date Summary View
    Apr 20, 2017
    The article was authored by scientists from the Medical University of South Carolina (MUSC) Hollings Cancer Center and Apogee Biotechnology and was published in Clinical Cancer ResearchThe Phase I study with YELIVA® in patients with advanced solid tumors successfully met its primary and secondary endpointsResults demonstrated that the drug is ...
    PDF
    Apr 19, 2017
    The R&D Day on BEKINDA® will take place on Thursday, April 27, 2017 in NYC from 8:00-10:00 EDT; A live webcast will be available through RedHill's websiteTop-line results from a Phase III study with BEKINDA® 24 mg for acute gastroenteritis and gastritis are expected in Q2/2017Top-line results from a Phase II study with BEKINDA® 12 mg...
    PDF
    Apr 18, 2017
    RedHill received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for two new patents covering BEKINDA® (RHB-102), expected to be valid until at least 2034, once granted BEKINDA® is a proprietary, bimodal extended-release, once-daily oral pill formulation of ondansetron, targeting several gastrointestinal in...
    PDF
    Apr 13, 2017
    The national marketing approval in Luxembourg completes the current approval process of RIZAPORT® under the European Decentralized Procedure (DCP); RIZAPORT® is also approved for marketing in Germany and a national Marketing Authorization Application (MAA) has been submitted in SpainRIZAPORT® is a proprietary oral thin film formulati...
    PDF
    Apr 5, 2017
    RedHill expects to initiate U.S. promotion of its two commercially-available gastrointestinal specialty products, Donnatal®1 and EnteraGam®2, in mid-2017 Under the terms of the agreement, RedHill will pay Entera Health royalties on net sales generated from the sale of EnteraGam® by RedHill TEL-AVIV, Israel, April 05, 2017 (GLOBE NEW...
    PDF
    Apr 4, 2017
    Orphan Drug designation allows RedHill to benefit from various development incentives to develop YELIVA® (ABC294640) for cholangiocarcinoma, as well as a seven-year marketing exclusivity period for the indication, if approved for marketing A Phase IIa clinical study with YELIVA® in patients with advanced, unresectable, intrahepatic and ex...
    PDF
    Mar 30, 2017
    TEL-AVIV, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal ...
    PDF
    Mar 22, 2017
    TEL-AVIV, Israel, March 22, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal ...
    PDF
    Mar 21, 2017
    A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn's disease (the MAP US study) is ongoing in the U.S. and additional countries The open-label extension study (the MAP US2 study) is intended to assess the safety and efficacy of RHB-104 in patients who have completed 26 weeks of trea...
    PDF
    Mar 13, 2017
    TEL-AVIV, Israel, March 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory di...
    PDF
    Page:
    1
    ... NextLast

    Subscribe to press releases